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Abstract
Objectives To examine whether the effect of tranexamic acid on the
risk of death and thrombotic events in patients with traumatic bleeding
varies according to baseline risk of death. To assess the extent to which
current protocols for treatment with tranexamic acid maximise benefits
to patients.
Design Prespecified stratified analysis of data from an international
multicentre randomised controlled trial (the CRASH-2 trial) with an
estimation of the proportion of premature deaths that could potentially
be averted through the administration of tranexamic acid.
Participants 13 273 trauma patients in the CRASH-2 trial who were
treated with tranexamic acid or placebo within three hours of injury and
trauma patients enrolled in UK Trauma and Audit Research Network,
stratified by risk of death at baseline (<6%, 6-20%, 21-50%, >50%).
Intervention Tranexamic acid (1 g over 10 minutes followed by 1 g over
eight hours) or matching placebo.
Main outcome measure Odds ratios and 95% confidence intervals for
death in hospital within four weeks of injury, deaths from bleeding, and
fatal and non-fatal thrombotic events associated with the use of
tranexamic acid according to baseline risk of death. Unless there was
strong evidence against the null hypothesis of homogeneity of effects
(P<0.001), the overall odds ratio was used as the most reliable guide to
the odds ratios in all strata.
Results Tranexamic acid was associated with a significant reduction in
all cause mortality and deaths from bleeding. In each stratum of baseline
risk, there were fewer deaths among patients treated with tranexamic
acid. There was no evidence of heterogeneity in the effect of tranexamic
acid on all cause mortality (P=0.96 for interaction) or deaths from
bleeding (P=0.98) by baseline risk of death. In those treated with
tranexamic acid there was a significant reduction in the odds of fatal and
non-fatal thrombotic events (odds ratio 0.69, 95% confidence interval
0.53 to 0.89; P=0.005) and a significant reduction in arterial thrombotic
events (0.58, 0.40 to 0.83; P=0.003) but no significant reduction in venous
thrombotic events (0.83, 0.59 to 1.17; P=0.295). There was no evidence
of heterogeneity in the effect of tranexamic acid on the risk of thrombotic
events (P=0.74). If the effect of tranexamic acid is assumed to be the
same in all risk strata (<6%, 6-20%, 21-50%, >50% risk of death at
baseline), the percentage of deaths that could be averted by
administration of tranexamic acid within three hours of injury in each
group is 17%, 36%, 30%, and 17%, respectively.
Conclusions Tranexamic acid can be administered safely to a wide
spectrum of patients with traumatic bleeding and should not be restricted
to the most severely injured.
Trial registration ISRCTN86750102.
Introduction
The CRASH-2 trial showed that a short course of tranexamic
acid given within three hours of injury to adult patients with
traumatic bleeding significantly reduces all cause mortality with
no apparent increase in the risk of adverse thrombotic events.1 2
As a result, tranexamic acid is now being incorporated into
trauma protocols around the world.3-5 These protocols generally
focus on the care of the most severely injured. Patients with a
high risk of death at baseline have the most to gain from the use
of life saving treatments because the absolute benefits of an
effective treatment tend to increase as the baseline risk increases.
On the other hand, there are more low risk trauma patients than
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high risk patients, and a large number of patients at low risk
might contribute more deaths than a smaller number of patients
at high risk. We carried out prespecified analyses of the
CRASH-2 trial data to examine how effects of treatment with
tranexamic acid vary according to the baseline risk of death in
patients with traumatic bleeding.We then used data from a large
hospital based trauma registry to assess the extent to which
current trauma protocols maximise the benefits to patients of
treatment with tranexamic acid.
Methods
We have previously used data from the CRASH-2 trial to
develop a prognostic model to identify patients with life
threatening traumatic bleeding.1 2 6 The model predicts all cause
mortality and includes the following baseline variables: age,
score on Glasgow coma scale, systolic blood pressure, heart
rate, respiratory rate, hours since injury, and type of injury. We
validated the model in a large sample of trauma patients from
the UK Trauma and Audit Research Network and found that
discrimination (C statistic above 0.80) and calibration were
good. A full description of derivation and validation of the
model has been published elsewhere.6
For these analyses, which were prespecified in the planned
statistical analysis, we used the prognostic model to stratify
patients in the CRASH-2 trial whose treatment was initiated
within three hours after injury into four strata of risk of mortality
(<6%, 6-20%, 21-50%, >50%). These strata were chosen
because we previously developed a simple risk chart to classify
patients into these risk categories.6We then examined the effect
of tranexamic acid (1 g over 10 minutes followed by 1 g over
eight hours) on all cause mortality, deaths from bleeding, and
thrombotic events (fatal and non-fatal myocardial infarction,
stroke, deep vein thrombosis, and pulmonary embolism) within
these strata. We used χ2 to assess heterogeneity in treatment
effects across subgroups.When subgroup effects are examined,
it is important to consider the possibility that an observed
subgroup effect might have arisen by chance alone. As
recommended in published guidelines on subgroup analysis, to
reduce the likelihood of making inappropriate subgroup
inferences we prespecified that unless there was strong evidence
against the null hypothesis of homogeneity of effects (that is,
P<0.001), the overall odds ratio would be considered the most
reliable guide to the approximate odds ratio in all strata.7 We
examined the effect of tranexamic acid on arterial (myocardial
infarction and stroke) and venous (deep vein thrombosis and
pulmonary embolism) thrombotic events combined and
separately.
We also used the prognostic model to estimate the number and
proportion of deaths at different levels of baseline risk in UK
trauma patients using data from the UK Trauma Audit and
Research Network. This analysis was conducted to assess the
distribution of risk of death in a representative trauma
population. The network dataset includes data from 60% of
hospitals receiving trauma patients in England andWales.8Data
are collected on patients who meet any of the following criteria:
death from injury at any point during admission, hospital stay
longer than three days, requirement for intensive or high
dependency care, requirement for transfer between hospitals
for specialist care. For these analyses, we included patients
presenting between 2000 and 2008 to hospitals participating in
the UK Trauma Audit and Research Network with an estimated
blood loss of at least 20% on the basis that these patients can
be considered to have severe haemorrhage. Estimated blood
loss was calculated in patients in the network by allocating an
estimated percentage of total volume of blood lost for each
injury code in the Abbreviated Injury Scale (AIS) dictionary by
blinded, then consensus, agreement from two emergency
physicians, as described in detail elsewhere.9 Finally, for each
patient we used the prognostic model described above to
estimate the predicted risk of death and then estimated the
proportion of premature deaths averted by applying the odds
ratio from the CRASH-2 trial to each of the risk strata.
Results
Table 1⇓ shows the characteristics of patients in the CRASH-2
trial and the UKTraumaAudit and Research Network according
to risk of death at baseline. Patients with a higher baseline risk
were older, had a lower systolic blood pressure, had a lower
score on the Glasgow coma scale, had a higher heart and
respiratory rate, and were more likely to have trauma from a
blunt injury than patients with a lower risk. Most CRASH-2
trial patients (97%) were from middle income countries, and
this frequency distribution was similar for all the risk strata.
Figure 1⇓ shows the effect of tranexamic acid on all cause
mortality by risk of death at baseline. In each stratum of baseline
risk, there were fewer deaths among patients treated with
tranexamic acid, although in the lowest risk strata, the effect
was not significant. There was no evidence of heterogeneity in
the effect of tranexamic acid on all cause mortality (P=0.96 for
interaction).
Figures 2⇓ and 3⇓ show the effect of tranexamic acid on death
from bleeding and on fatal and non-fatal thrombotic events by
baseline risk of death. There was no evidence of heterogeneity
in the effect of tranexamic acid on deaths from bleeding
(P=0.98) or on thrombotic events (P=0.74). There was no
significant reduction in all other causes of death combined (that
is, non-bleeding deaths) (odds ratio 0.97, 95% confidence
interval 0.86 to 1.09) and no evidence of heterogeneity according
to baseline risk (P=0.99).
Table 2⇓ shows the effect of tranexamic acid on fatal and
non-fatal thrombotic events in patients treated within three hours
of injury. In patients treated with tranexamic acid there was a
significant reduction in the risk of fatal and non-fatal thrombotic
events (odds ratio 0.69, 95% confidence interval 0.53 to 0.89;
P=0.005) and a significant reduction in arterial thrombotic events
(0.58, 0.40 to 0.83; P=0.003). There was no evidence of
heterogeneity in the effect of tranexamic acid on arterial
thrombotic events (P=0.91) or venous thrombotic events by
baseline risk (P=0.85). There was also no significant reduction
in the risk of venous thrombotic events with tranexamic acid
(0.83, 0.59 to 1.17; P=0.295).
Figure 4⇓ shows the distribution of patients in the UK Trauma
Audit and Research Network by baseline risk. There were many
more low risk patients than high risk patients. If we assume that
the effect of tranexamic acid is the same in all risk strata
(constant odds ratio), the estimated overall percentage of deaths
that could be avoided by administering tranexamic acid, split
according to each risk stratum (<6%, 6-20%, 21-50%, >50%)
is 17%, 36%, 30%, and 17%, respectively. Figure 5⇓ shows the
number of deaths that could potentially be averted through the
use of tranexamic acid in patients in the UK Trauma Audit and
Research Network by baseline risk of death.
Discussion
The beneficial effects of tranexamic acid in reducing all cause
mortality and deaths from bleeding in patients with traumatic
bleeding do not seem to vary significantly by baseline risk of
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death. Tranexamic acid reduced the odds of death from bleeding
by about 30% in each of the baseline risk strata studied and
reduced the odds of thrombotic events by about 30%. Once
again, this reduction did not vary significantly by baseline risk
of death. Taken together, these data suggest that tranexamic
acid can be administered safely to a wide spectrum of patients
with traumatic bleeding and that its use should not be restricted
to those with themost severe haemorrhage. Absence of evidence
of heterogeneity by baseline risk of death, however, should not
be taken as evidence of absence. In particular, in the lowest risk
group the precision of the estimated effect is low, and there
remains some uncertainty.
Strengths and weaknesses
The data examined are from a large randomised placebo
controlled trial with well concealed allocation, blinded outcome
assessment, and minimal loss to follow up.We prespecified this
analysis of the effect of tranexamic acid stratified by baseline
risk of death in the planned statistical analysis in 2010 before
un-blinding. Specifically, we stated that we would conduct
“subgroup analyses according to baseline risk of mortality. We
will develop a prognostic model including all the baseline
variables (age, sex, systolic blood pressure, heart rate, respiratory
rate, GlasgowComa Score, number of hours since injury, central
capillary refill time and type of injury). This model will be
derived only from the control group. We will categorise the
patients according to tertiles of risk and we will report the
relative and absolute measures of effect for each category.” The
only substantial deviation from this plan was that we created
four risk strata rather than three. This was done so that the risk
groups analysed corresponded with those in a risk score that we
had previously developed for use by emergency physicians.6
The risk score categories in turn were based on previous research
and the views of clinical users.6
The data examined here are a subset of the entire CRASH-2
trial. As most trauma protocols restrict use of tranexamic acid
to patients who are within three hours of injury, we also
restricted our analyses to these patients. Given that our results
are based on a subgroup analysis, they should be interpreted
cautiously. On the other hand, there was also a reduction in the
risk of fatal and non-fatal myocardial infarction and fewer
thrombotic events with tranexamic acid (relative risk 0.64, 95%
confidence interval 0.42 to 0.97; P=0.035) in the main trial
analysis of patients treated up to eight hours after injury.1While
there could be grounds for scepticism about the reduction in
arterial thrombotic events with tranexamic acid, the data are
reassuring that there is no increased risk. As regards the absence
of evidence of an interaction between the effect of tranexamic
acid and baseline risk of death, it is important to bear in mind
that this could be because of a lack of statistical power for the
interaction tests.
That we analysed data from a randomised controlled trial using
a prognostic model that was derived from the same trial might
be considered a weakness. On the other hand, the prognostic
model we used has good external calibration and discrimination,
and there are few models available that can be reliably applied
to the trauma population included in the CRASH-2 trial. The
revised trauma score, one of the most widely used scores, was
developed many years ago, has several methodological
limitations, and showed poor calibration in the CRASH-2 and
UK Trauma Audit and Research Network datasets (data
available on request).
Establishing cause of death in trauma patients can be difficult,
and any inaccuracy might have affected our estimate of the
effect of tranexamic acid on fatal thrombotic events. Theremight
also have been inaccuracy in the diagnosis of non-fatal events.
The diagnosis of myocardial infarction is particularly
challenging in trauma patients, many of whom are anaesthetised
or sedated. Increases in creatine kinase MB isoenzyme activity
are hard to interpret because of muscle injury, and we did not
collect data on troponin. Diagnostic inaccuracy, however, tends
to obscure treatment effects and would not readily explain the
observed reduction in thrombotic events with tranexamic acid.
Potential biological mechanisms
Tranexamic acid reduces the risk of death from haemorrhage
and seems to reduce the risk of arterial thrombotic events. It is
possible that by reducing bleeding, tranexamic acid reduces
myocardial oxygen demand and increases oxygen supply. It is
also possible that the reduction in arterial thrombotic events
could be mediated through an anti-inflammatory effect of
tranexamic acid.10 11
Implications for patients
These results have important implications for the care of trauma
patients. Firstly, they suggest that tranexamic acid can safely
be used in all trauma patients with or at risk of severe bleeding,
as in the inclusion criteria used in the CRASH-2 trial, and not
just in the most severely injured. Secondly, the observed
reduction in the risk of arterial events with tranexamic acid
suggests that the absolute benefits from administration of
tranexamic acid are likely to be greatest in older trauma patients,
who at any given level of severity of injury have a higher
baseline risk of death from haemorrhage and thrombotic
events.6 12Clinical concern about an increased risk of ischaemic
cardiac events might be a reason to give rather than to withhold
tranexamic acid. It is worth noting that trials of tranexamic acid
in patients undergoing cardiac surgery, a group at high risk of
cardiac events, provide no evidence of any increased risk.13 We
acknowledge that estimating the risk of severe bleeding is a
challenging ongoing process that uses not only physiological
variables but other variables such as laboratory measurements
and response to treatments. Physicians will use all this
information and their clinical judgment when deciding whether
to use tranexamic acid. In situations of uncertainty, however,
physicians can use the prognostic model to support the decision
making process and should certainly consider administering
tranexamic acid to patients with a risk of death higher than 5%.
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What is already known on this topic
Tranexamic acid given to patients with traumatic bleeding within three hours of injury significantly reduces mortality with no apparent
increase in adverse thrombotic events
What this study adds
The beneficial effect of tranexamic acid on all cause mortality or deaths from bleeding is not affected by baseline risk of death
There were fewer thrombotic events with tranexamic acid with no evidence of heterogeneity by baseline risk
Use of tranexamic acid should not be limited to high risk patients
TARN already has ethical approval (PIAG section 60) for research on
the anonymised data that are stored securely on the University of
Manchester server.
Data sharing: The CRASH-2 trial data are publicly available via an online
data sharing website called FREEBIRD that can be accessed at https:
//ctu2.lshtm.ac.uk/freebird/. Unpublished calibration data available from
the corresponding author. Consent was not obtained for sharing data
but the presented data are anonymised and risk of identification is low.
1 CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events,
and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a
randomised, placebo-controlled trial. Lancet 2010;376:23-32.
2 CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding
trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Lancet 2011;377:1096-101.
3 TXA implementation pages—how to do it. www2.le.ac.uk/departments/cardiovascular-
sciences/research/population-research-and-clinical-trials/emergency-medicine-group/
research/injury/txa-implementation-pages-how-to-do-it.
4 Committee on Tactical Combat Casualty Care. Tranexamic acid (TXA) in tactical combat
casualty care. Guideline revision recommendation. 2011. www.medicalsci.com/files/
tranexamic_acid__txa__in_tactical_combat_casualty_care.pdf.
5 Luz L, Sankarankutty A, Passos E, Rizoli S, Fraga G, Nascimento Jr B. Tranexamic acid
for traumatic hemorrhage. Rev Col Bras Cir. 2012;39:77-80.
6 Perel P, Prieto-Merino D, Shakur H, Clayton T, Lecky F, Bouamra O, et al. Predicting
early death in patients with traumatic bleeding: development and validation of prognostic
model. BMJ 2012;345:e5166.
7 Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria
to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
8 Trauma Audit and Research Network. www.tarn.ac.uk/.
9 Guly HR, Bouamra O, Hatton M, Dark P, Coats T, Driscoll P, et al. Vital signs and estimated
blood loss in patients with major trauma: testing the validity of the ATLS classification of
hypovolaemic shock. Resuscitation 2011;82:556-9.
10 Godier A, Roberts I, Hunt B. Tranexamic acid: less bleeding and less thrombosis. Crit
Care 2012;16:135.
11 Jiménez J, Iribarren J, Lorente L, Rodríguez J, Hernandez D, Nassar I, et al. Tranexamic
acid attenuates inflammatory response in cardiopulmonary bypass surgery through
blockade of fibrinolysis: a case control study followed by a randomized double-blind
controlled trial. Crit Care 2007;11:R117.
12 Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous
thromboembolism after major trauma. N Engl J Med 1994;331:1601-6.
13 Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical
bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054.
Accepted: 18 August 2012
Cite this as: BMJ 2012;345:e5839
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e5839 doi: 10.1136/bmj.e5839 (Published 11 September 2012) Page 4 of 8
RESEARCH
Tables
Table 1| Characteristics of patients with traumatic bleeding in CRASH-2 and Trauma Audit and Research Network (TARN) by risk of death
at baseline. Figures are numbers (percentages) unless stated otherwise
Baseline risk
>50%21-50%6-20%≤5%
CRASH-2
1190 (9)1848 (14)5395 (41)4840 (36)No of patients
1002 (84)1533 (83)4457 (83)4111 (85)Men
980 (82)1316 (71)3186 (59)2761 (57)Blunt injury
35 (25-49)35 (25-48)32 (25-44)27 (22-36)Mean (IQR) age (years)
80 (60-90)80 (70-100)90 (80-110)100 (90-120)Mean (IQR) systolic blood pressure (mm Hg)
118 (98-130)110 (97-124)106 (92-120)100 (90-112)Mean (IQR) heart rate (per min)
24 (16-30)24 (20-30)24 (20-28)20 (18-24)Mean (IQR) respiratory rate (per min)
4 (3-6)10 (7-13)15 (13-15)15 (15-15)Mean (IQR) Glasgow coma score (total)
TARN (Trauma Audit and Research Network)
743 (6)1456 (11)4912 (36)6486 (48)No of patients
537 (72)861 (59)3239 (66)4954 (76)Men
716 (96)1312 (90)4339 (88)5303 (82)Blunt injury
42 (27-67)56 (31-82)52 (35-67)30 (22-41)Mean (IQR) age (years)
103 (85-130)120 (96-156)126 (105-147)130 (118-142)Mean (IQR) systolic blood pressure (mm Hg)
111 (94-130)100 (81-120)90 (76-108)85 (75-98)Mean (IQR) heart rate (per min)
22 (18-27)21 (18-26)20 (17-24)18 (16-22)Mean (IQR) respiratory rate (per min)
3 (3-6)10 (7-15)15 (14-15)15 (15-15)Mean (IQR) Glasgow coma score (total)
IQR=interquartile range.
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Table 2| Effect of tranexamic acid on fatal and non-fatal thrombotic events in patients with traumatic bleeding. Figures are numbers
(percentages) of patients experiencing each event
P valueOdds ratio (95% CI)Placebo (n=6589)Tranexamic acid (n=6684)
0.0050.69 (0.53 to 0.89)140 (2.1)98 (1.5)Any event
0.0030.58 (0.40 to 0.83)80 (1.2)47 (0.7)Any arterial event
0.0050.49 (0.30 to 0.81)46 (0.7)23 (0.3)Myocardial infarction
0.1280.69 (0.43 to 1.11)40 (0.6)28 (0.4)Stroke
0.2950.83 (0.59 to 1.17)71 (1.1)60 (0.9)Any venous event
0.5480.88 (0.58 to 1.33)47 (0.7)42 (0.6)Pulmonary embolism
0.6410.88 (0.52 to 1.50)28 (0.4)25 (0.4)Deep vein thrombosis
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Figures
Fig 1 Deaths from all causes in patients with traumatic bleeding according to treatment with tranexamic acid (P=0.96 for
heterogeneity)
Fig 2 Death from bleeding in patients with traumatic bleeding according to treatment with tranexamic acid (P=0.98 for
heterogeneity)
Fig 3 Fatal and non-fatal thrombotic events in patients with traumatic bleeding according to treatment with tranexamic acid
(P=0.74 for heterogeneity)
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Fig 4 Distribution of patients with traumatic bleeding in UK Trauma Audit and Research Network by baseline risk of death
Fig 5 Distribution of estimated premature deaths in patients with traumatic bleeding potentially averted with administration
of tranexamic acid
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